A negative second trimester triple test and absence of specific ultrasonographic markers may decrease the need for genetic amniocentesis in advanced maternal age by 60%

Prenat Diagn. 2002 Jan;22(1):59-63. doi: 10.1002/pd.238.

Abstract

Objective: A study was conducted to evaluate the sensitivity of combining a second trimester triple test and targeted ultrasound in order to detect Down syndrome in women undergoing amniocentesis over 35 years of age.

Methods: Women over 35 years of age underwent a triple test and an ultrasound examination for chromosomal markers immediately prior to genetic amniocentesis.

Results: One thousand and six women were examined. Four hundred and thirty seven were triple test-positive and in 195 cases ultrasonographic abnormalities were observed. Thirteen had Down syndrome and eight had other chromosomal abnormalities. All women with Down syndrome babies were triple test-positive and seven also had ultrasonographic markers. Three of eight women who had babies with chromosomal aberrations other then Down syndrome were also triple test-positive.

Conclusions: The use of the triple test as a screening tool in our population would reduce the number of amniocenteses by 60%, while no cases of Down syndrome would be missed. Ultrasonographic markers have added little to this population. Three non-Down syndrome chromosomal abnormalities and two Down syndrome mosaic cases would be missed by this approach.

MeSH terms

  • Adult
  • Amniocentesis*
  • Chorionic Gonadotropin / blood
  • Chromosome Aberrations
  • Down Syndrome / diagnosis*
  • Estriol / blood
  • Female
  • Gestational Age*
  • Humans
  • Karyotyping
  • Maternal Age
  • Middle Aged
  • Pregnancy
  • Pregnancy, High-Risk
  • Prenatal Diagnosis*
  • Sensitivity and Specificity
  • Ultrasonography, Prenatal*
  • alpha-Fetoproteins / analysis

Substances

  • Chorionic Gonadotropin
  • alpha-Fetoproteins
  • Estriol